More substantively, now -- there will be a series of comparisons -- to Amgen, Libby and likely Baxter and Abbott -- and maybe even Amazon's health units. [Depends on how ambitious I get in the Rockies -- while she naps.]
Here is what Pfizer spent on in Q4 -- the prior three quarters were detailed here, in more or less real time. Just use the search box, if you are abidingly curious. But I'd call this a spending tie, between Merck and Pfizer (spoiler alert: Amgen blew them both away in 2025 -- over $13 million, or by almost 30%). Here is the detail, on Pfizer:
. . .[Senate:] Vaccine Policy, Coverage and Access; Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; H.R. 5256 - 340B Access ACT; Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule; Drug Pricing; PBM Reform; H.R. 4581 - 340B PATIENTS Act of 2025; H.R. 5509 - Safe Step Act; S. 2903 - Safe Step Act; S. 2296 - National Defense Authorization Act (NDAA) for Fiscal Year 2026; S. 1053 - FIGHT China Act; Cancer Research; Centers for Disease Control and Prevention (CDC) Policies. . . .
[US House:] H.R. 5256 - 340B Access ACT; Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule; H.R. 4581 - 340B PATIENTS Act of 2025; 340B Reform; 340B HHS Pilot Program Model; Insurance Coverage of Prescription Drugs; Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage; PBM Reform; P.L. 117-169 - Inflation Reduction Act (IRA) of 2022; Drug Pricing; Medicare/Medicaid. . . .
. . . . [Various Agencies:] International Supply Chain; Global Access; Market Access; Most Favored Nation Policies; Tariffs; Generics; Foreign Freeriding Issues; Non-Tariff Trade Barriers; Trade Issues. . . .
Now you know. Merck, tomorrow -- then Amgen; then. . . Lilly. Grin.
नमस्ते
No comments:
Post a Comment